Company Background

Influx Healthtech Limited is a leading contract development and manufacturing organisation (CDMO) producing nutraceuticals, veterinary formulations, herbal supplements, and dietary wellness products. The company operates US FDA and WHO GMP certified manufacturing facilities catering to domestic and international markets.

Product Portfolio & Manufacturing Capabilities

Product categories include nutraceutical capsules, softgels, tablets, powders, liquid formulations, veterinary boluses, and herbal extracts. Manufacturing is conducted across multiple dosage form lines with capacity for both small-batch clinical trials and large-scale commercial production.

Investment Highlights

1. Regulatory Compliance: US FDA and WHO GMP certifications position the company to directly service international pharma and wellness brands.

2. Export Revenue Growth: Export revenues growing at 35%+ YoY driven by demand from US, Europe, and Middle East nutraceutical brands.

3. CDMO Model Advantage: Asset-light CDMO model generates higher return ratios versus branded pharma peers, with predictable revenue visibility through long-term manufacturing contracts.

4. Veterinary Segment: Emerging veterinary formulations business provides diversification into the fast-growing animal healthcare market.

CBA Research View — FY26 Factsheet

CBA views Influx Healthtech as a high-quality CDMO play in the nutraceuticals and wellness sector. The company's international regulatory approvals, growing export pipeline, and diversification into veterinary formulations make it a differentiated investment in the healthcare manufacturing space.

Risks

Key risks include regulatory audit exposure, customer concentration in CDMO contracts, raw material cost pressures, and currency risk associated with export revenues.